Sporadic extranodal Rosai–Dorfman–Destombes disease treated with tocilizumab

Overview of attention for article published in Pediatric Blood and Cancer, April 2022

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age
Above-average Attention Score compared to outputs of the same age and source (53rd percentile)

Mentioned by

twitter: 4 X users

Readers on

mendeley: 2 Mendeley

So far, Altmetric has seen 4 X posts from 4 X users, with an upper bound of 14,896 followers.

@GuiperiniMD @GauravGoyalMD @Histiocytosis @uabmedicine Have you tried tocilizumab? https://t.co/DFZ0rFXuCq

4-29-2022: Wilmington, Delaware: After other treatments had failed, the all-purpose antioxidant, Actemra (tocilizumab), was called in to rescue people with "sporadic extranodal Rosai-Dorfman-Destombes disease." Pay Manuel Gonzales https://t.co/vEdowKx…

#Blood&;Cancer Sporadic extranodal Rosai–Dorfman–Destombes disease treated with tocilizumab https://t.co/3L9rH8Pjx2

Sporadic extranodal Rosai–Dorfman–Destombes disease treated with tocilizumab https://t.co/aEpPMDiPG9

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity.